

Press Release

Västra Frölunda, Sweden, November 3, 2011

## **Election Committee 2012**

---

**It was decided at the Artimplant Annual General Meeting on May 4, 2011 that the Election Committee would comprise the Chairman of the Board of Directors plus three members appointed by the three largest stockholders, according to voting power, as of September 30, 2011.**

The composition of the Election Committee must be announced no later than six months prior to the Annual General Meeting.

Up to the 2012 Annual General Meeting the Election Committee shall comprise the following:

Lars Peterson, private stockholder and chairman of the Election Committee

John Arnold, private stockholder

Bo Kaunitz, private stockholder

Anders Cedronius, private stockholder and Chairman of the Board of Directors

Stockholders who wish to contact the Election Committee can do so by e-mail at [susan.linke@artimplant.com](mailto:susan.linke@artimplant.com) or by telephone on +46 (0)31-746 56 00.

---

### **For further information, please contact:**

Anders Cedronius

E-mail: [anders.cedronius@cedronius.se](mailto:anders.cedronius@cedronius.se)

Telephone: +4686225809

Kjell Thörnbring, CEO

E-mail: [kjell.thornbring@artimplant.com](mailto:kjell.thornbring@artimplant.com)

Telephone: +46703119025

Further information at [www.artimplant.com](http://www.artimplant.com) where one also can subscribe to future press releases;  
[www.artimplant.com/investors-media/subscribe-to-press-releases.html](http://www.artimplant.com/investors-media/subscribe-to-press-releases.html)

### **Artimplant**

Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon<sup>®</sup>, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

### **Forward-looking statements**

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of



Artimplant AB  
Hulda Mellgrens gata 5  
SE-421 32 Västra Frölunda  
SWEDEN

Phone +46 (0)31 746 56 00  
Fax +46 (0)31 746 56 60  
Web [www.artimplant.com](http://www.artimplant.com)  
Reg. No. 556404-8394

risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

*This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on November 3 at 9:00 AM (Swedish time).*